title: Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
abstract: The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL). However, that study was completed before rituximab (R) was introduced into clinical practice. Here we report a phase II study of the THP-COP regimen combined with R (R-THP-COP) every 3 weeks. The complete response and 3-year overall survival rates was 63% and 53%, respectively, and no deaths were related to the regimen. We conclude that the R-THP-COP regimen is safe and effective for patients with DLBCL. Based on these results, a randomized controlled trial of rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and R-THP-COP as a phase III study is ongoing.
authors: First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
authors: Senji
authors: S
authors: Kasahara
authors: Takeshi
authors: T
authors: Hara
authors: Hisashi
authors: H
authors: Tsurumi
authors: Naoe
authors: N
authors: Goto
authors: Jun-Ichi
authors: J
authors: Kitagawa
authors: Nobuhiro
authors: N
authors: Kanemura
authors: Takeshi
authors: T
authors: Yoshikawa
authors: Hideko
authors: H
authors: Goto
authors: Kenji
authors: K
authors: Fukuno
authors: Toshiki
authors: T
authors: Yamada
authors: Michio
authors: M
authors: Sawada
authors: Takeshi
authors: T
authors: Takahashi
authors: Tsuyoshi
authors: T
authors: Takami
authors: Hisataka
authors: H
authors: Moriwaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D012107:Research Design; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone